Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
Armin Ghobadi(Washington University in St. Louis), Veronika Bachanová(University of Minnesota Medical Center), Krish Patel, Jae H. Park(Memorial Sloan Kettering Cancer Center), Ian W. Flinn(Tennessee Oncology), Peter A. Riedell(University of Chicago), Carlos Bachier(Sarah Cannon), Catherine Diefenbach(NYU Langone Health), Carol Wong(Fate Therapeutics (United States)), Cara Bickers(Fate Therapeutics (United States)), Lilly Wong(Fate Therapeutics (United States)), Deepa Patel(Fate Therapeutics (United States)), Jode Goodridge(Fate Therapeutics (United States)), Matthew Denholt(Fate Therapeutics (United States)), Bahram Valamehr(Fate Therapeutics (United States)), Rebecca Elstrom(Fate Therapeutics (United States)), Paolo Strati(The University of Texas MD Anderson Cancer Center)
Cited by 108Open Access
Abstract
Related Papers
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al.|Journal of Clinical Oncology|2014|5.5k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee, Bianca Santomasso, Frederick L. Locke et al.|Biology of Blood and Marrow Transplantation|2018|3.4k